Return to Listing

42 result(s) for Hematologic Cancers

PI Name Protocol # Title
Stephen Spurgeon IRB00007195 A Phase II Proof of Concept Trial to Study Kinase Inhibition in Relapsed/Refractory Acute Leukemias: Using a Comprehensive in Vitro Kinase Inhibitor Panel to Select Individualized Targeted Therapies
Richard Maziarz IRB00009375 A Phase 1-2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells after Partially Mismatched, Related, T Cell-Depleted HSCT
Emma Scott IRB00009398 A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age
Kim-Hien Dao IRB00010262 Prospective Evaluation of ruxolitinib Efficacy for CNL/aCML Patients with Mutation of CSF3R
Stephen Spurgeon IRB00010383 A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-Lag-3 (BMS-986016) in Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas
Michael Heinrich IRB00010537 A Phase I, Multicenter, Open-Label Study of Oral ABL001 in Patients with Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Emma Scott IRB00011097 A Feasibility Study of Myeloablative BEAM Allogeneic Transplantation Followed by Oral Ixazomib Maintenance Therapy in Patients with Relapsed High-Risk Multiple Myeloma
Stephen Spurgeon IRB00011766 A Phase Ib Feasibility Study of Personalized Kinase Inhibitor Therapy Combined with Induction Chemotherapy in Acute Myeloid Leukemia in Patients who Exhibit in vitro Kinase Inhibitor Sensitivity
Brandon Hayes-Lattin IRB00011894 Protocol CCTL019B2206: A multicenter study of apheresis collection of peripheral blood mononuclear cells (PBMC) in patients with CD19 expressing malignancies who could be eligible for a CTL019 clinical research trial
Brandon Hayes-Lattin IRB00011960 Long Term Follow-Up of Patients Exposed to Lentiviral- Based CD19 directed CART Cell Therapy
Michael Heinrich STUDY00015085 A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
Alexey Danilov STUDY00015136 A Phase 1B Dose Escalation and Dose Expansion Study of ONO/GS-4059 in Combination with Other Targeted Anti-cancer Therapies in Subjects with B-cell Malignancies
Rachel Cook STUDY00015214 A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies
Stephen Spurgeon STUDY00015255 IIT: A Phase II study of Obinutuzumab (GA-101) in Combination with Ibrutinib (I) for the Treatment of Relapsed Mantle Cell Lymphoma (ML29535)
Craig Okada STUDY00015315 Phase 1/2 Study of Intratumoral G100 With or Without Pembrolizumab in Patients with Follicular Non-Hodgkin's Lymphoma
Elie Traer STUDY00015601 A Phase 1, Multi-center, Open-label Study of IMGN779 Administered Intravenously in Adult Patients with Relapsed/Refractory CD33-positive Acute Myeloid Leukemia
Eva Medvedova STUDY00015608 Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Laura Newell STUDY00015619 A phase 1/2 study of Vadastuximab Talirine (SGN-CD33A) in combination with Azacitidine in patients with previously untreated international prognostic scoring system (IPSS) intermediate -2 or high-risk Myelodysplastic Syndrome (MDS).
Alexey Danilov STUDY00015680 A Phase Ib/II, Open label, Single Arm, Multi-center, Dose Escalation Trial of Intravenous BI 836826 in Combination with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Alexey Danilov STUDY00015747 A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL)
Andy Chen STUDY00015836 A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ASN002 in Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia and Advanced Solid Tumors
Emma Scott STUDY00015863 A Phase 1/2 Open label trial of SL-401 in combination with Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
Rachel Cook STUDY00015903 A Randomized, Phase II Study of CX-01 Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia
Rachel Cook STUDY00015953 A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Kim-Hien Dao STUDY00015977 [NCI CIRB] The National Myelodysplastic Syndromes (MDS) Study
Rachel Cook STUDY00015993 A Phase I Dose Finding Study Evaluating Safety and Feasibility of BPX-701 in Patients with Relapsed or Refractory Myeloid Neoplasm
Raymond Bergan STUDY00016113 Molecular Mechanisms of Tumor Evolution and Resistance to Therapy
Alexey Danilov STUDY00016140 A Phase I/II study of Syk inhibitor entospletinib (GS-9973) in combination with obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and B-cell malignancies
Richard Maziarz STUDY00016189 A Phase 1 Non-Randomized, Open-Label/Phase 2 Randomized, Blinded Study of ProTmune (ex vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects with Hematologic Malignancies
Uma Borate STUDY00016338 A Phase 1/1b Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 alone and in combination with cytarabine (Ara-C) in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome With Wild-Type TP53
Kim-Hien Dao STUDY00016363 A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
Rachel Cook STUDY00016429 A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects with FLT3/ITD AML in First Complete Remission
Uma Borate STUDY00016475 A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
Stephen Spurgeon STUDY00016624 A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Emma Scott STUDY00016649 Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation
Andy Chen STUDY00016830 [NCI CIRB] A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Elie Traer STUDY00016896 A Multicenter Phase 1, Open-Label Study of DCC-3014 to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Malignancies
Emma Scott STUDY00016905 Multicenter, Single-arm, Phase 2 Study to Determine the Efficacy for the Combination of Daratumumab (DARA) plus Durvalumab (DURVA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) Who Have Progressed on DARA while on a DARA- containing Regimen as the Most Recent Multiple Myeloma Therapy. “Fusion MM-005”
Michael Heinrich STUDY00016941 Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Kim-Hien Dao STUDY00016964 A Phase 1/1b, Multicenter, Open-label, Dose-Escalation Study of FT-2102 as a Single Agent and in Combination with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation
Gary Takahashi STUDY00017126 A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma
Emma Scott STUDY00017199 A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared with CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080